ADAG

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Adagene Inc

NASDAQ | ADAG

1.97

USD

$0.00

(

0.00%

)

At Close (As of Dec 4, 2025)

$84.84M

Market Cap

-

P/E Ratio

-0.64

EPS

$3.16

52 Week High

$1.30

52 Week Low

HEALTHCARE

Sector

ADAG Chart

Recent Chart
Price Action

ADAG Technicals

Tags:

ADAG Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

Revenue & Profitability

Earnings Performance

ADAG Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $89M
Total Current Assets $88M
Cash And Cash Equivalents At Carrying Value $85M
Cash And Short Term Investments $85M
Inventory -
Current Net Receivables $8.3K
Total Non Current Assets $1.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $2.6M
Other Non Current Assets -
Total Liabilities $39M
Total Current Liabilities $38M
Current Accounts Payable $4.2M
Deferred Revenue -
Current Debt -
Short Term Debt $18M
Total Non Current Liabilities $560K
Capital Lease Obligations $284K
Long Term Debt $417K
Current Long Term Debt $18M
Long Term Debt Noncurrent -
Short Long Term Debt Total $18M
Other Current Liabilities $16M
Other Non Current Liabilities -
Total Shareholder Equity $51M
Treasury Stock -
Retained Earnings -$311M
Common Stock $5.9K
Common Stock Shares Outstanding $36M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$30M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $926K
Capital Expenditures $34K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $1.1M
Cashflow From Financing $3.8M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$33M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$823K
Total Revenue $103K
Cost Of Revenue $926K
Costof Goods And Services Sold $926K
Operating Income -$36M
Selling General And Administrative $7.3M
Research And Development $29M
Operating Expenses $36M
Investment Income Net -
Net Interest Income $2.9M
Interest Income $3.8M
Interest Expense $852K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $926K
Income Before Tax -$33M
Income Tax Expense -$18K
Interest And Debt Expense -
Net Income From Continuing Operations -$33M
Comprehensive Income Net Of Tax -
Ebit -$33M
Ebitda -$32M
Net Income -$33M

ADAG News

ADAG Profile

Adagene Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Adagene Inc. is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focusing on the innovative development of monoclonal antibody therapies for oncology. Leveraging its proprietary technologies, Adagene is pioneering next-generation antibody drug candidates aimed at improving efficacy and reducing side effects in cancer treatment. With a robust pipeline of drug candidates, the company is well-positioned to make significant advancements in the biopharmaceutical landscape, targeting unmet medical needs in cancer care.

LPTX
+368.57%
$2.05
PAVS
-7.35%
$0.03
KALA
+4.21%
$0.96
NVDA
+2.11%
$183.38
ASST
-6.99%
$0.97
PLUG
0.00%
$2.23
PMCB
+54.21%
$1.21
ONDS
+3.02%
$9.19
INTC
-7.44%
$40.50
TNFA
+48.17%
$6.92
QCLS
+48.17%
$6.92
KITT
-25.00%
$1.17
IPG
-1.95%
$24.57
RR
+8.76%
$4.59
RGTI
+15.43%
$30.06
TSLA
+1.74%
$454.53
AXDX
-61.36%
$0.03
ACHR
+7.18%
$8.95
IXHL
+7.13%
$0.47
VHAI
+100.00%
$0.00
BYND
-0.80%
$1.24
SOFI
+1.82%
$29.60
NIO
+4.59%
$5.01
VALE
+1.95%
$13.56
BITF
-0.32%
$3.10
AAL
-1.51%
$14.34
QBTS
+14.55%
$28.73
BBD
+1.39%
$3.63
ADAP
-15.14%
$0.05
INHD
+1.01%
$0.13
DNN
+5.18%
$2.84
F
+0.38%
$13.14
BMNR
+7.90%
$36.32
AMZN
-1.40%
$229.11
AAPL
-1.21%
$280.70
SOND
-23.45%
$0.12
SMR
+13.45%
$22.85
BMNU
+15.34%
$9.32
RMBL
+60.50%
$3.21
NFLX
-0.55%
$103.38
IONZ
-25.48%
$3.10
LNW
-3.71%
$86.22
WBD
-0.12%
$24.54
KVUE
+0.11%
$16.99
ADD
-25.47%
$0.05
RIVN
+3.02%
$18.06
BAC
+0.12%
$54.16
IRBT
-10.61%
$3.03
IREN
+5.66%
$46.45
SRM
+53.27%
$10.30
PFE
+0.50%
$25.70
CLSK
+3.72%
$15.03
TWOH
+9.09%
$0.00
IONQ
+12.55%
$54.76
PLTD
-1.04%
$6.66
T
+0.27%
$25.39
BTBT
+2.14%
$2.38
HPE
+2.87%
$22.90
MARA
-0.24%
$12.44
GOOGL
-0.62%
$317.62
GRAB
+0.56%
$5.30
SNAP
+1.30%
$7.76
PFSA
-4.57%
$0.18
CIFR
+6.44%
$19.83
META
+3.42%
$661.53
SOUN
+8.65%
$12.80
WULF
+4.64%
$15.10
CRWV
+8.05%
$85.75
ITUB
+1.89%
$8.07
PLTR
+1.04%
$177.92
QUBT
+12.51%
$13.58
WLGS
-5.57%
$0.04
VZ
+1.45%
$41.26
EOSE
+15.05%
$15.59
MTSR
-0.35%
$70.50
RKLB
+10.39%
$49.37
BMY
+5.61%
$50.96
STAI
+32.35%
$0.30
PLRZ
+104.51%
$14.50
WMT
+0.37%
$114.84
BURU
+7.45%
$0.24
ASTS
+18.24%
$72.65
AMD
-0.74%
$215.98
HIMS
+7.99%
$40.03
MRVL
-2.00%
$98.19
AFMD
-34.94%
$0.18
MU
-3.20%
$226.65
ORCL
+3.17%
$214.33
USAR
+24.67%
$17.48
RIG
-0.44%
$4.43
KR
-4.62%
$63.14
MSPR
+15.26%
$0.32
HBAN
+0.35%
$17.10
ALIT
-0.46%
$2.16
APLD
+6.06%
$31.14
VIVK
+11.18%
$0.10
MSFT
+0.65%
$480.84
OWL
+2.55%
$16.06
JOBY
+7.72%
$15.76
BTG
+1.33%
$4.56
LPTX
+368.57%
$2.05
PAVS
-7.35%
$0.03
KALA
+4.21%
$0.96
NVDA
+2.11%
$183.38
ASST
-6.99%
$0.97
PLUG
0.00%
$2.23
PMCB
+54.21%
$1.21
ONDS
+3.02%
$9.19
INTC
-7.44%
$40.50
TNFA
+48.17%
$6.92
QCLS
+48.17%
$6.92
KITT
-25.00%
$1.17
IPG
-1.95%
$24.57
RR
+8.76%
$4.59
RGTI
+15.43%
$30.06
TSLA
+1.74%
$454.53
AXDX
-61.36%
$0.03
ACHR
+7.18%
$8.95
IXHL
+7.13%
$0.47
VHAI
+100.00%
$0.00
BYND
-0.80%
$1.24
SOFI
+1.82%
$29.60
NIO
+4.59%
$5.01
VALE
+1.95%
$13.56
BITF
-0.32%
$3.10
AAL
-1.51%
$14.34
QBTS
+14.55%
$28.73
BBD
+1.39%
$3.63
ADAP
-15.14%
$0.05
INHD
+1.01%
$0.13
DNN
+5.18%
$2.84
F
+0.38%
$13.14
BMNR
+7.90%
$36.32
AMZN
-1.40%
$229.11
AAPL
-1.21%
$280.70
SOND
-23.45%
$0.12
SMR
+13.45%
$22.85
BMNU
+15.34%
$9.32
RMBL
+60.50%
$3.21
NFLX
-0.55%
$103.38
IONZ
-25.48%
$3.10
LNW
-3.71%
$86.22
WBD
-0.12%
$24.54
KVUE
+0.11%
$16.99
ADD
-25.47%
$0.05
RIVN
+3.02%
$18.06
BAC
+0.12%
$54.16
IRBT
-10.61%
$3.03
IREN
+5.66%
$46.45
SRM
+53.27%
$10.30
PFE
+0.50%
$25.70
CLSK
+3.72%
$15.03
TWOH
+9.09%
$0.00
IONQ
+12.55%
$54.76
PLTD
-1.04%
$6.66
T
+0.27%
$25.39
BTBT
+2.14%
$2.38
HPE
+2.87%
$22.90
MARA
-0.24%
$12.44
GOOGL
-0.62%
$317.62
GRAB
+0.56%
$5.30
SNAP
+1.30%
$7.76
PFSA
-4.57%
$0.18
CIFR
+6.44%
$19.83
META
+3.42%
$661.53
SOUN
+8.65%
$12.80
WULF
+4.64%
$15.10
CRWV
+8.05%
$85.75
ITUB
+1.89%
$8.07
PLTR
+1.04%
$177.92
QUBT
+12.51%
$13.58
WLGS
-5.57%
$0.04
VZ
+1.45%
$41.26
EOSE
+15.05%
$15.59
MTSR
-0.35%
$70.50
RKLB
+10.39%
$49.37
BMY
+5.61%
$50.96
STAI
+32.35%
$0.30
PLRZ
+104.51%
$14.50
WMT
+0.37%
$114.84
BURU
+7.45%
$0.24
ASTS
+18.24%
$72.65
AMD
-0.74%
$215.98
HIMS
+7.99%
$40.03
MRVL
-2.00%
$98.19
AFMD
-34.94%
$0.18
MU
-3.20%
$226.65
ORCL
+3.17%
$214.33
USAR
+24.67%
$17.48
RIG
-0.44%
$4.43
KR
-4.62%
$63.14
MSPR
+15.26%
$0.32
HBAN
+0.35%
$17.10
ALIT
-0.46%
$2.16
APLD
+6.06%
$31.14
VIVK
+11.18%
$0.10
MSFT
+0.65%
$480.84
OWL
+2.55%
$16.06
JOBY
+7.72%
$15.76
BTG
+1.33%
$4.56
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.